Starting October 22, 2026, prescription drug importation by mail into the United States is expected to get much harder, and for many patients it may stop working altogether. Mailed packages of FDA-regulated products can no longer use the simple postal customs process. They now need either formal customs entry or a new electronic process called Entry Type 13, and both require a customs bond and detailed filings. An association of Canadian international pharmacies warns that most personal prescription orders will no longer be deliverable. This applies to mail from every country, including India and Canada. It does not affect medicine from U.S. pharmacies or hospitals.

A member of my group called her supplier in India this week to place a large order. They told her they had put all sales to the United States on hold and hoped it would get sorted out. If you buy any medicine from overseas, this affects you too.

What changes on October 22

In June 2026, U.S. Customs and Border Protection (CBP) published a rule that ends duty-free treatment for small packages arriving by international mail and replaces the old process with a new one. Most of the rule took effect in July. October 22 is the date CBP set for one specific piece. From that day, mail packages holding products that another federal agency regulates, including anything under the FDA, can no longer use the simpler postal process.

Those packages now have two options. One is formal customs entry, the full process businesses use for larger shipments. The other is Entry Type 13, a new electronic filing that CBP switched on in its computer system on September 22. CBP created it partly as an easier path for small mail packages that need FDA information.

Easier is relative. To file Entry Type 13, the buyer or a customs broker acting for them has to be the “importer of record,” post a customs bond, and file electronically in CBP’s trade system. The filing includes an importer number, a 10-digit tariff code for each product, the country of origin, duty owed, the postal tracking number, and whatever data the FDA requires. A patient technically can do this alone, but realistically almost no one will. CBP’s own paperwork estimate for the program assumes about 10 filers, each handling around 200,000 entries a year. It’s built for businesses.

Why prescriptions are likely to get stuck

The new paperwork is only half the problem. The other half is whether the medicine itself is allowed in.

The Canadian International Pharmacy Association (CIPA) says one company, Zonos, acts as customs broker for nearly all major international postal systems, and most of those systems have no other broker doing that job. CIPA says that under the new rule and FDA policy, Zonos will be prevented from acting as importer of record for any prescription drug that’s commercially available in the United States. Zonos’s own published guidance says the FDA’s personal-use exception doesn’t apply when effective treatment is already available here, and that a pharmacy marketing to Americans fails the FDA’s conditions no matter what paperwork the patient sends.

That’s why CIPA concludes that a new filing option doesn’t solve anything. Its assessment is that, unless something changes, virtually all routine personal prescription orders from licensed Canadian and international pharmacies won’t be able to reach U.S. patients. Keep in mind that CIPA represents pharmacies that sell to Americans, so it has a direct stake in this. Its prediction is well reasoned, but it’s an industry assessment, not a government finding.

It applies to every country

The rule covers mail from every country. A package from a pharmacy in Canada faces the same process as one from India or the United Kingdom. Suppliers in India and elsewhere are pausing U.S. orders because their shipping partners can’t clear the packages, not because the U.S. singled out any one country. The rule doesn’t name any country or any drug.

Why the government made this change

Nothing in the rule suggests it was aimed at patients ordering their own medicine. It’s part of a much broader change to how the U.S. handles the enormous volume of low-value packages coming into the country, most of them online purchases.

CBP gives three main reasons in the rule. The first is volume. CBP processed more than 1.36 billion small duty-free packages in 2024, almost ten times the 139 million it handled in 2015, and most of that is online shopping. The second is smuggling. CBP says criminals send fentanyl, counterfeits, and other illegal goods in small parcels because they expect them to slip through. The third is money. CBP’s analysis estimates the new mail process will bring in about $163 million to $166 million a year in tariffs.

This was already on the way. A federal law passed in July 2025 permanently ends the duty-free small package exemption on July 1, 2027. The new rule moves that up and builds the process for mail.

Prescription drugs got pulled in because the FDA regulates them. When CBP tightened the requirements for mail packages that need oversight from another federal agency, prescription drugs were swept into the new system along with everything else the FDA covers.

I read the rule myself, and I didn’t find any discussion of patients who mail-order their own prescriptions. My read is that personal prescription drug importation got caught in a net built for online shopping and smuggling. That’s my interpretation. The government hasn’t said it either way.

How prescription drug importation worked before

Importing prescription drugs for personal use was already illegal in most cases. Many foreign versions of drugs aren’t FDA-approved, even when the same medicine is sold here under another label. What made it possible was the FDA’s personal importation policy, which lets FDA staff use discretion and release some shipments.

That policy has always been narrow. For a serious condition, FDA staff may allow a shipment when effective treatment may not be available in the U.S., the product isn’t marketed to U.S. residents, it doesn’t pose an unreasonable risk, the patient states in writing that it’s for personal use, the amount is generally no more than a three-month supply, and the patient names the U.S. doctor responsible for their care. The policy is guidance for FDA staff. It doesn’t give patients a legal right to import anything.

Drugs that are easy to get in the U.S. never fit that policy well. Plenty of those shipments arrived anyway. Under the old mail process, CBP received far less usable information about individual packages. The new electronic filings give CBP and the FDA much more information about each shipment, which makes systematic screening easier.

Who this affects

Anyone who relies on prescription drug importation by mail is affected. That includes people who buy brand-name drugs from Canadian pharmacies to save money, people who order low-cost generics from online pharmacies in India, and people who order repurposed drugs from overseas suppliers. It also includes anyone getting a drug that isn’t approved in the U.S. at all, which was always the hardest case under FDA policy.

One example shows why this matters for appendix cancer. Appendix cancer patients in the UK have told me they couldn’t get Ibrance through the NHS for their appendix cancer, even when their tumor biology gave their doctors a reason to consider it. Ibrance is available in the UK for certain breast cancers, but not routinely for appendix cancer. Some of them have instead bought generic palbociclib, the same active drug, from India. Indian companies began selling generic versions in 2023 after Pfizer’s Indian patent expired, and news reports put the savings at more than 90 percent.

This U.S. customs change doesn’t affect those UK patients. But it’s exactly the kind of access it threatens for patients in the United States, where some people with appendix cancer take Ibrance off-label under their oncologist’s care (I’ve written about Dr. Andrew Lowy’s work on CDK4/6 inhibitors and Jeremy’s experience on Ibrance). Sometimes an overseas pharmacy is an affordable way to get a medicine your own health system won’t cover for your cancer. One caution applies no matter where the pills come from. Palbociclib can drop white blood cell counts and requires regular blood tests, so anyone taking it needs an oncologist monitoring them.

Supplements are FDA-regulated too, as food, so mailed supplements fall under the same new filing requirements. Controlled drugs, such as opioid pain medicine, benzodiazepines, and stimulants, don’t have the same personal-use mail exception, and the October 22 change doesn’t alter those restrictions.

If a mailed drug doesn’t qualify, the FDA’s own description of its mail process says the package can be detained, and the FDA sends the recipient a notice with a chance to respond. If the response doesn’t resolve the problem, the product is refused, and some refused drugs can be destroyed instead of returned to the sender. That process isn’t new for October 22. What changes is how much information arrives with each package.

Who this does not affect

If you fill your prescriptions at a U.S. pharmacy, use a U.S. mail-order pharmacy, or get treatment at a U.S. hospital, this change doesn’t apply to you. That includes chemotherapy. Many generic drugs on U.S. pharmacy shelves are made in India, but they come in through commercial shipping channels that already use full customs entry. The October 22 mail change doesn’t apply to that normal commercial supply chain.

The rule also leaves the customs exemption for personal items you carry with you when you travel unchanged. FDA’s existing rules about bringing medicine home still apply.

For my members outside the United States, this is a U.S. rule about medicine shipped into the U.S. If you get your medicine in your own country, it doesn’t affect you.

What I would do now

If you depend on prescription drug importation by mail, talk to your doctor this week about getting it from a U.S. source. Some drugs people order overseas are sold here too. Ivermectin, for example, is FDA-approved in the U.S. as an antiparasitic, so a U.S. doctor can prescribe it and a U.S. pharmacy can fill it. Prices vary a lot between pharmacies, so it’s worth calling around. If you’re weighing whether a repurposed drug is worth taking at all, my post on checking research papers yourself may help.

Rushing a big order before the deadline isn’t a safe bet. An order placed now may not reach the border before the 22nd, and the FDA’s policy generally contemplates no more than a three-month supply anyway.

If you want this changed, contact your two U.S. senators and your representative before October 22. Ask for an exception for personal-use prescriptions. That would protect patients without weakening the rule’s goals on smuggling or tariffs, which makes it a reasonable request no matter where you sit politically.

What is still unknown

As of October 7, 2026, I haven’t found any FDA or CBP guidance creating a special exception for personal prescription shipments. CBP has issued technical guidance for the new customs process, including Entry Type 13, but I haven’t found an agency statement explaining how ordinary patients ordering prescriptions from overseas pharmacies are expected to get through it. Either agency could still issue guidance, create an exception, or change the timing. I’ll update this post when that happens.

Frequently asked questions

Is the U.S. banning drugs from India?

No. The October 22 change is a customs process change for medicine mailed to individuals from any country. It doesn’t single out India or any specific drug.

Will my U.S. pharmacy run out of medicine because of this?

This change applies to mailed packages, not the commercial drug supply that stocks U.S. pharmacies and hospitals. That supply already goes through full customs entry.

Is personal prescription drug importation legal?

In most cases it has been illegal for years. The FDA has used discretion to allow some small personal shipments, generally up to a three-month supply, but that policy gives no legal right to import.